Literature DB >> 34078312

Risk factors for preeclampsia and eclampsia at a main referral maternity hospital in Freetown, Sierra Leone: a case-control study.

N Stitterich1, J Shepherd2, M M Koroma3, S Theuring4.   

Abstract

BACKGROUND: In the African region, 5.6% of pregnancies are estimated to be complicated by preeclampsia and 2.9% by eclampsia, with almost one in ten maternal deaths being associated with hypertensive disorders. In Sierra Leone, representing one of the countries with the highest maternal mortality rates in the world, 16% of maternal deaths were caused by pregnancy-induced hypertension in 2016. In the light of the high burden of preeclampsia and eclampsia (PrE/E) in Sierra Leone, we aimed at assessing population-based risk factors for PrE/E to offer improved management for women at risk.
METHODS: A facility-based, unmatched observational case-control study was conducted in Princess Christian Maternity Hospital (PCMH). PCMH is situated in Freetown and is the only health care facility providing 'Comprehensive Emergency Obstetric and Neonatal Care services' throughout the entire country. Cases were defined as pregnant or postpartum women diagnosed with PrE/E, and controls as normotensive postpartum women. Data collection was performed with a questionnaire assessing a wide spectrum of factors influencing pregnant women's health. Statistical analysis was performed by estimating a binary logistic regression model.
RESULTS: We analyzed data of 672 women, 214 cases and 458 controls. The analysis yielded several independent predictors for PrE/E, including family predisposition for PrE/E (AOR = 2.72, 95% CI: 1.46-5.07), preexisting hypertension (AOR = 3.64, 95% CI: 1.32-10.06), a high mid-upper arm circumflex (AOR = 3.09, 95% CI: 1.83-5.22), presence of urinary tract infection during pregnancy (AOR = 2.02, 95% CI: 1.28-3.19), presence of prolonged diarrhoea during pregnancy (AOR = 2.81, 95% CI: 1.63-4.86), low maternal assets (AOR = 2.56, 95% CI: 1.63-4.02), inadequate fruit intake (AOR = 2.58, 95% CI: 1.64-4.06), well or borehole water as the main source of drinking water (AOR = 2.05, 95% CI: 1.31-3.23) and living close to a waste deposit (AOR = 1.94, 95% CI: 1.15-3.25).
CONCLUSION: Our findings suggest that systematic assessment of identified PrE/E risk factors, including a family predisposition for PrE/E, preexisting hypertension, or obesity, should be performed early on in ANC, followed by continued close monitoring of first signs and symptoms of PrE/E. Additionally, counseling on nutrition, exercise, and water safety is needed throughout pregnancy as well as education on improved hygiene behavior. Further research on sources of environmental pollution in Freetown is urgently required.

Entities:  

Keywords:  Eclampsia; Freetown; Preeclampsia; Risk factors; Sierra Leone

Year:  2021        PMID: 34078312     DOI: 10.1186/s12884-021-03874-7

Source DB:  PubMed          Journal:  BMC Pregnancy Childbirth        ISSN: 1471-2393            Impact factor:   3.007


  19 in total

1.  The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study.

Authors:  Emma Nilsson; Helena Salonen Ros; Sven Cnattingius; Paul Lichtenstein
Journal:  BJOG       Date:  2004-03       Impact factor: 6.531

2.  Risk factors for pre-eclampsia in Mulago Hospital, Kampala, Uganda.

Authors:  Paul Kiondo; Gakenia Wamuyu-Maina; Gabriel S Bimenya; Nazarius Mbona Tumwesigye; Julius Wandabwa; Pius Okong
Journal:  Trop Med Int Health       Date:  2011-12-13       Impact factor: 2.622

3.  The origins and outcomes of triplet and quadruplet pregnancies in Nova Scotia: 1980 to 2001.

Authors:  Krista A Cassell; Colleen M O'connell; Thomas F Baskett
Journal:  Am J Perinatol       Date:  2004-11       Impact factor: 1.862

4.  Risk factors for pre-eclampsia in Lagos, Nigeria.

Authors:  Rose I Anorlu; Nnamdi C Iwuala; Celestine U Odum
Journal:  Aust N Z J Obstet Gynaecol       Date:  2005-08       Impact factor: 2.100

Review 5.  Global and regional estimates of preeclampsia and eclampsia: a systematic review.

Authors:  Edgardo Abalos; Cristina Cuesta; Ana L Grosso; Doris Chou; Lale Say
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-06-07       Impact factor: 2.435

6.  Preeclampsia and blood lead (and other metals) in Lubumbashi, DR Congo.

Authors:  Paul Musa Obadia; Tony Kayembe-Kitenge; Vincent Haufroid; Célestin Banza Lubaba Nkulu; Benoit Nemery
Journal:  Environ Res       Date:  2018-07-26       Impact factor: 6.498

Review 7.  Maternal infection and risk of preeclampsia: systematic review and metaanalysis.

Authors:  Agustín Conde-Agudelo; José Villar; Marshall Lindheimer
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

8.  Placental malarial infection as a risk factor for hypertensive disorders during pregnancy in Africa: a case-control study in an urban area of Senegal, West Africa.

Authors:  C T Ndao; A Dumont; N Fievet; S Doucoure; A Gaye; J Y Lehesran
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

9.  Malaria and pre-eclampsia in an area with unstable malaria transmission in Central Sudan.

Authors:  Ishag Adam; Elhassan M Elhassan; Ahmed A Mohmmed; Magdi M Salih; Mustafa I Elbashir
Journal:  Malar J       Date:  2011-09-07       Impact factor: 2.979

10.  Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis.

Authors:  Ver Luanni Bilano; Erika Ota; Togoobaatar Ganchimeg; Rintaro Mori; João Paulo Souza
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more
  1 in total

1.  The Effect of Selenium Supplementation on Clinical Outcomes, Metabolic Profiles, and Pulsatility Index of the Uterine Artery in High-Risk Mothers in Terms of Preeclampsia Screening with Quadruple Test: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial : Selenium and preeclampsia.

Authors:  Elahe Mesdaghinia; Farah Shahin; Amir Ghaderi; Daryoush Shahin; Mohammad Shariat; Hamidreza Banafshe
Journal:  Biol Trace Elem Res       Date:  2022-02-28       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.